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Recent publications, reviewed elsewhere,1 proved the fea-sibility of developing multidimensional classifiers based 
on the urinary proteome that are associated with chronic kid-
ney disease,2 urothelial cell carcinoma,3 prostate cancer,4 or 
coronary heart disease.5 However, these urinary proteomic 
markers were mainly established in selected patients matched 
with controls or in cohorts of diseased patients. In 2012, we 
identified in a preliminary case–control study 85 urinary pep-
tides, mainly up- or downregulated collagen fragments, that 
discriminated 19 hypertensive patients with asymptomatic 
diastolic left ventricular dysfunction from 19 controls.6 With 
adjustments applied for multiple testing, 3 urinary peptide 
biomarkers remained significant.6 In a subsequent cross-sec-
tional study, we demonstrated that left ventricular diastolic 
dysfunction was associated with this proteomic signature in a 
random population sample.7 A study in the same population 
revealed that the urinary proteome predicted progression of 
chronic kidney disease from grade 2 or lower to stage 3 or 
higher.8 In the light of our previous observations,6–8 we inves-
tigated in a random population sample whether the urinary 
proteome predicts cardiovascular events over and beyond tra-
ditional risk factors.
Methods
Study Participants
The Ethics Committee of the University of Leuven approved the 
Flemish Study on Environment, Genes and Health Outcomes.9,10 
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Recruitment started in 1985 and continued until 2004. The initial par-
ticipation rate was 78.0%. The participants were repeatedly followed 
up.9,10 From May 2005 until May 2010, we mailed an invitation letter 
to 1208 former participants for a follow-up examination. However, 
153 were unavailable because they had died earlier (n=26), because 
they had been institutionalized or were too ill (n=27), or because 
they had moved out of the area (n=100). Of the remaining 1055 for-
mer participants, 828 renewed informed consent. The participation 
rate was therefore 78.5%. We excluded 37 participants from analy-
sis because urine samples for urinary proteomics were unavailable 
(n=22) or because they were lost to follow-up (n=15). Thus, the out-
come cohort included 791 participants (for details, see Figure S1 in 
the online-only Data Supplement).
Assessment of Outcome
At annual intervals, we ascertained vital status through 6 October 
2014 via the Belgian Population Registry in Brussels, Belgium. We 
obtained the International Classification of Disease codes for the 
immediate and underlying causes of death from the Flemish Registry 
of Death Certificates. For all 791 participants, we collected informa-
tion on the incidence of nonfatal events either via a follow-up visit at 
the examination center with repeat administration of the same stan-
dardized questionnaire as used at baseline (n=637) or via a structured 
telephone interview (n=119).
Coronary events included sudden death, myocardial infarction, 
acute coronary syndrome, new-onset angina pectoris, ischemic car-
diomyopathy, and coronary revascularization. Cardiac events addi-
tionally included heart failure, pulmonary heart disease, new-onset 
atrial fibrillation, life-threatening arrhythmias, and high-degree atrio-
ventricular block requiring pacemaker implantation. Cardiovascular 
events comprised cardiac end points, stroke, transient ischemic at-
tack, aortic aneurysm, arterial embolism, and revascularization of 
peripheral arteries. To assess the symptoms associated with heart fail-
ure, we administered the London School of Hygiene questionnaires 
on cardiovascular and respiratory symptoms and dyspnea. Physicians 
ascertained the diseases reported on the death certificates or by the 
questionnaires and interviews against the medical records of general 
practitioners or hospitals. For all end points within a category, we 
censored participants from analysis after the occurrence of the first 
event.
Urinary Proteomics
To assess the urinary proteome-based HF1 classifier, 24-h urine 
samples were processed and analyzed using capillary electropho-
resis coupled with mass spectrometry as described previously.11 
The online-only Data Supplement (pages 2–3) gives detailed 
information on the preparation and processing of the urine sam-
ples. The data (on abundance) of the predefined urinary peptide 
biomarkers were combined into a single summary variable, using 
the support-vector machine–based MosaCluster software, version 
1.7.0. In the present study, we used the previously published mul-
tidimensional classifier HF1, which is associated with decreased 
left ventricular function and which combines information from 
85 peptide fragments identified in 19 patients with diastolic LV 
dysfunction and 19 controls.6 How support-vector machine mod-
eling establishes the HF1 classifier is described in the online-
only Data Supplement (pages 3–4). In addition, the online-only 
Data Supplement provides information on the peptides making up 
HF1 (Table S1) and sequenced peptides with known amino-acid 
sequence (Table S2).
Other Measurements
Blood pressure was the average of 5 consecutive auscultatory read-
ings obtained according to European guidelines with a standard mer-
cury sphygmomanometer with the participant in the seated position 
for at least 10 minutes. As described elsewhere, we applied a stringent 
quality control program to the blood pressure measurements, looking 
for digit and number preference.12,13 Hypertension was a blood pres-
sure of at least 140 mm Hg systolic or 90 mm Hg diastolic or use of 
antihypertensive drugs. Body mass index was weight in kilograms 
divided by height in meters squared. Venous blood samples were 
drawn for measurement of plasma glucose and serum total and high-
density lipoprotein cholesterol, creatinine, and γ-glutamyltransferase 
(index of alcohol intake). Glomerular filtration rate was derived by 
the Chronic Kidney Disease Epidemiology Collaboration equation.14 
Diabetes mellitus was a self-reported diagnosis, a condition men-
tioned on the death certificate or in records held by general practitio-
ners or hospitals, antidiabetic drug intake, a fasting plasma glucose 
level of at least 126 mg/dL, or a random blood glucose of at least 
200 mg/dL.15
Statistical Analysis
For database management and statistical analysis, we used the SAS 
system, version 9.3 (SAS Institute Inc., Cary, NC). Means were com-
pared using the large-sample z-test or ANOVA and proportions by 
Fisher exact test. Statistical significance was a 2-sided significance 
level of 0.05.
In exploratory analyses, we plotted incidence rates by tertiles 
of the urinary biomarker, while standardizing for sex and age 
group (<40 years; 40–60 years; >60 years) by the direct method. 
In categorical analyses with adjustments applied for sex and age, 
we plotted the cumulative incidence of cardiovascular and cardiac 
endpoints by thirds of the HF1 distribution. We used Cox regres-
sion to compute standardized hazard ratios, which for continuous 
variables express the risk associated with a 1-standard deviation 
(SD) increment in the urinary biomarker. All models accounted 
for clustering of failure times within pedigrees by fitting a shared 
frailty model. We checked the proportional hazard assumption us-
ing the Kolmogorov-type supremum test. The baseline character-
istics considered as covariables in Cox regression were sex, age, 
body mass index, systolic blood pressure, fasting plasma glucose, 
serum creatinine, the total-to-high-density lipoprotein cholesterol 
ratio, γ-glutamyltransferase (as index of alcohol intake), smok-
ing, history of cardiovascular disease, and treatment with diuretics 
(thiazides, loop diuretics, and aldosterone antagonists), β-blockers, 
inhibitors of the renin–angiotensin system (angiotensin-converting 
enzyme inhibitors or angiotensin type-1 receptor blockers), vaso-
dilators (calcium channel blockers or α-blockers), or other anti-
hypertensive drugs. We identified covariables to be retained in the 
analyses by a step-down procedure, removing the least significant 
covariable at each step until all P values of covariables were <0.15. 
We applied the generalized R2 statistic to assess the contribution of 
HF1 and systolic blood pressure to risk over and beyond other risk 
factors. We calculated the multivariable-adjusted 5-year absolute 
risk of a cardiovascular or cardiac event across thirds of the distri-
butions of HF1 and systolic blood pressure.
Finally, we determined optimal discrimination limits for HF1 by 
maximizing Younden’s index (the maximum of sensitivity plus speci-
ficity minus 1). We then assessed the added prognostic accuracy of 
the optimized thresholds, using the integrated discrimination im-
provement (IDI) and the continuous net reclassification improvement 
(NRI).16 IDI is the difference between the discrimination slopes of the 
basic model and the basic model extended with HF1. The discrimi-
nation slope is the difference in predicted probabilities (%) between 
subjects with and without end point. To calculate NRI,16 we predicted 
in each subject the 5-year risk for an event from a Cox model with 
and without HF1. If P(up/event) is the percentage of subjects with events 
whose predicted probability is increased by adding HF1 to the model 
and if P(up/nonevent) is the percentage of subjects without events whose 
predicted probability is increased, then NRI equals 2×[P(up/event)–P(up/
nonevent)].
Results
Characteristics of Participants
Of 791 participants, 400 (50.6%) were women. All subjects 
were White Europeans. Mean values (SD) in all participants 
combined were 51.2 (15.7) years (interquartile range [IQR], 
41.3–61.8 years) for age, 129.6 (17.7) and 79.7 (9.6) mm Hg 
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for systolic and diastolic blood pressure, 26.5 (4.3) kg/m2 
for body mass index, and 5.26 (0.97) mmol/L for total cho-
lesterol. Of 3955 systolic and 3955 diastolic blood pressure 
readings, only 10 (0.13%) ended on an uneven number. With 
regards to number preferences, the 5 consecutive blood pres-
sure readings included 3 identical systolic or diastolic values 
in 340 instances (4.3%) and 5 identical values in only a single 
participant.
Of all participants, 340 (43.0%) had hypertension, of 
whom 209 (61.5%) were on antihypertensive drug treat-
ment, 27 (3.4%) had a history of diabetes mellitus, and 27 
(3.4%) reported previous cardiovascular disease. The anti-
hypertensive drug classes used were diuretics in 84 (10.6%) 
participants, β-blockers in 124 (15.7%), inhibitors of the 
renin–angiotensin system in 68 (8.6%), and vasodilators in 
39 (4.9%). Among 209 treated patients, 122 (58.4%) were 
on monotherapy; 69 (33.0%) were taking 2 drug classes; 
and 18 (8.6%) were taking ≥3. Of 400 women and 391 men, 
80 (20.0%) women and 80 (20.5%) men were smokers and 
225 (56.3%) women and 323 (82.6%) men reported intake 
of alcohol. In smokers, median tobacco use was 13 ciga-
rettes per day (IQR, 7–20 cigarettes per day). In drinkers, 
the median alcohol consumption was 8 g per day (IQR, 3–14 
g per day).
Table 1 lists the characteristics of participants by thirds of 
the HF1 distribution (median; −1.03; IQR, –1.60 to –0.44). 
Age, body mass index, central obesity, blood pressure, serum 
creatinine, blood glucose and γ-glutamyltransferase, and the 
total-to- high-density lipoprotein cholesterol ratio all (P≤0.002) 
increased with higher HF1 category, whereas estimated glo-
merular filtration rate decreased (P<0.0001). The prevalence of 
hypertension, being treated for hypertension, having a history 
Table 1. Baseline Characteristics of 791 Participants by Thirds of the HF1 Distribution
Characteristic <–1.42 –1.42 to –0.68 ≥–0.68 P Value
Number in category 264 263 264
Number of subjects, %
  Women 138 (52.3) 133 (50.6) 129 (48.9) 0.74
  Smokers 57 (21.6) 60 (22.8) 43 (16.3) 0.14
  Drinking alcohol 185 (70.1) 191 (72.6) 172 (65.2) 0.17
  Hypertension 80 (30.3) 94 (35.7) 166 (62.9)§ <0.0001
  Antihypertensive treatment 37 (14.0) 50 (19.0) 122 (46.2)§ <0.0001
  History of CVD 7 (2.7) 4 (1.5) 16 (6.1)† 0.011
  History of diabetes mellitus 3 (1.1) 7 (2.7) 17 (6.4)* 0.003
Mean (SD) of characteristic
  Age, y 45.6 (15.3) 50.4 (14.3)‡ 57.5 (15.0)§ <0.0001
  Body mass index, kg/m2 25.6 (3.8) 26.0 (4.0) 28.0 (4.8)§ <0.0001
  Waist-to-hip ratio 0.85 (0.08) 0.87 (0.08)* 0.90 (0.08)§ <0.0001
  Office blood pressure, mm Hg
   Systolic pressure 126.6 (17.3) 127.9 (16.7) 134.3 (18.2)§ <0.0001
   Diastolic pressure 78.4 (9.6) 79.7 (9.5) 81.1 (9.6) 0.004
   Mean arterial pressure 94.4 (10.7) 95.8 (10.5) 98.9 (10.7)‡ <0.0001
  Heart rate, bpm 62.6 (8.6) 63.4 (9.3) 64.4 (11.1) 0.10
  Biochemical data
   Serum creatinine, μmol/L 81.8 (13.3) 83.7 (13.1) 86.7 (19.8)* 0.002
   eGFR, mL/min/1.73 m2 83.9 (16.4) 80.2 (16.2)† 76.3 (16.2)† <0.0001
   Total cholesterol, mmol/L 5.13 (0.95) 5.32 (0.98)* 5.33 (0.98) 0.028
   HDL cholesterol, mmol/L 1.45 (0.34) 1.45 (0.37) 1.37 (0.32)† 0.008
   THR 3.70 (0.98) 3.84 (1.03) 4.06 (1.05)* 0.0002
   Blood glucose, mmol/L 4.85 (0.56) 4.88 (0.58) 5.09 (1.07)† 0.0007
   γ-GT, units/L 21 (11, 40) 24 (12, 57)* 26 (13, 55) 0.0005
CVD indicates cardiovascular disease; eGFR, estimated glomerular filtration rate calculated according to the Chronic Kidney 
Disease Epidemiology Collaboration equation formula, as described in reference 14; γ-GT, γ-glutamyltransferase; HDL, high-
density lipoprotein; and THR, total-to-HDL cholesterol ratio. Office blood pressure was the average of 5 consecutive readings. 
Hypertension was an office blood pressure of ≥140 mm Hg systolic, or ≥90 mm Hg diastolic, or use of antihypertensive drugs. 
For γ-glutamyltransferase, values are geometric mean (interquartile range). Diabetes mellitus was a self-reported diagnosis, a 
condition mentioned on the death certificate or in records held by general practitioners or hospitals, antidiabetic drug intake, a 
fasting glucose level of at least 126 mg/dL, or a random blood glucose at least 200 mg/dL. P values denote the significance of 
the differences in prevalence rates or means across thirds of the HF1 distribution.
Significance of the difference with the adjacent lower third: *P≤0.05; †P≤0.01; ‡P≤0.001; §P≤0.0001.
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of cardiovascular disease, or diabetes mellitus increased with 
HF1. The proportions of women, smokers, and average heart 
rate did not differ across HF1 categories (P≥0.10).
Incidence of Events
Median follow-up was 6.1 years (5th to 95th percentile, 3.7–7.4). 
During 4552 person-years of follow-up, 35 participants died, 11 
of cardiovascular disease, and 63 experienced a fatal or nonfatal 
cardiovascular event (14.4 events per 1000 person-years). Fatal 
or nonfatal cardiac event occurred in 45 participants (10.1 events 
per 1000 person-years) and coronary events in 22 (4.9 events per 
1000 person-years). Table S3 lists the cause-specific cardiovas-
cular mortality and morbidity for the study cohort.
Risk Associated with HF1 Categories
Crude rates of cardiovascular, cardiac, and coronary events 
increased across thirds of the HF1 distribution (Table S4; 
P≤0.0032) with a similar trend for all-cause mortality 
(P=0.057). The incidence of fatal combined with nonfatal 
cardiovascular (P=0.014) and cardiac (P=0.009) end points, 
standardized for sex and age group, increased across thirds 
of the HF1 distribution (Figure 1), whereas the trends for 
all-cause mortality and coronary events did not reach sig-
nificance (P≥0.10). For cardiovascular (P=0.046) and cardiac 
(P=0.028) events, the cumulative incidence ran a significantly 
higher course in the top compared with the low third of the 
HF1 distribution (Figure 2). These estimates were standard-
ized to the means of the distributions of sex and age in the 
whole study population. Based on these results, the risk of 
cardiovascular and cardiac events was carried forward in mul-
tivariable-adjusted analyses.
Multivariable-Adjusted Risk Associated with the 
HF1 Biomarker
The step-down selection procedure identified sex, age, fast-
ing blood sugar, smoking, and treatment with vasodilators as 
significant covariables of the risk of a cardiovascular or cardiac 
event (Table S5). Table 2 shows the multivariable-adjusted 
hazard ratios associated with a 1-SD increment in HF1. All 
Cox models complied with the proportional hazards assump-
tion (P≥0.056). In all 791 participants, HF1 was a significant 
predictor of fatal and nonfatal cardiovascular (P=0.029) and 
cardiac events (P=0.018), whereas systolic blood pressure was 
not (P=0.85 and P=0.66, respectively). The generalized R2 sta-
tistics for entering HF1 or systolic blood pressure (Table 2) 
as predictor in these models were 0.59 versus 0.01 for car-
diovascular events and 0.69 versus 0.03 for cardiac events. 
Sensitivity analyses, from which we excluded 71 participants 
with previous cardiovascular disease (Table 2), or in all 791 
participants with hypertension forced into the Cox models 
as additional covariable (P values for HF1, ≤0.042; data not 
shown) were confirmatory. Figure 3 shows the 5-year absolute 
risk of a cardiovascular or cardiac event in relation to systolic 
blood pressure (Figure 3A and 3B) at different levels of HF1 
or in relation to HF1 (Figure 3C and 3D) at different levels 
of systolic blood pressure. The analyses were standardized to 
the average of the distributions in the whole study population 
(mean or ratio) of sex, age, fasting plasma glucose, smoking, 
and treatment with vasodilators. Figure 3 illustrates that HF1, 
being significantly related to outcomes (P≤0.033), was more 
informative than systolic pressure (P≥0.54) in predicting car-
diovascular and cardiac events over a 5-year span.
Improvement of Prognostic Accuracy
By maximizing Younden’s index (Table 3), we determined 
optimal thresholds for HF1 in predicting cardiovascular or 
cardiac events. Sensitivity of the optimized thresholds ranged 
from 59% to 86% for cardiovascular events and from 53% to 
58% for cardiac events. Specificity ranged from 46% to 75% 
and from 80% to 81%, respectively. In all 791 participants 
(Table 4), both IDI and NRI reached significance for cardio-
vascular and cardiac events (P≤0.006). In 720 participants 
free of cardiovascular disease at entry (Table 4), IDI and NRI 
were significant for cardiovascular events (P<0.0001) and 
reached borderline significance for cardiac events (P≤0.086).
Discussion
The key findings of our study were as follows: (i) over a 
follow-up period of ≈5 years, the multidimensional urinary 
classifier HF1 predicted the incidence of fatal and nonfatal 
cardiovascular and cardiac events; (ii) after optimizing the 
HF1 thresholds, adding HF1 to Cox models, including base-
line cardiovascular risk factors, significantly improved prog-
nostic accuracy; (iii) HF1 was more informative than systolic 
blood pressure in the short-term prediction of cardiovascular 
and cardiac events. Our current findings are in line with a pre-
vious publication showing that in the same cohort, the early 
diastolic peak velocity of the mitral annulus (e′) predicted 
the incidence of fatal combined with nonfatal cardiovascular 
events over a 5-year follow-up period.17 Over a similar fol-
low-up, mild and moderate-to-severe diastolic left ventricu-
lar dysfunction predicted all-cause mortality in the Olmsted 
County study with hazard ratios amounting to 8.3 and 10.2, 
respectively (P<0.001).18 As previously demonstrated in 
Figure 1. Incidence of fatal and nonfatal cardiovascular and 
cardiac events by tertiles of the distributions of the HF1 in 791 
participants. Incidence rates were standardized for sex and age 
group (<40 years, 40–60 years, and >60 years) by the direct 
method. The number of end points contributing to the rates is 
shown. P values are for trend.
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case–control6 and proof-of-concept7 studies, HF1 associates 
with diastolic left ventricular dysfunction.
Under physiological conditions, ≈70% of the urinary 
protein content originates from the kidney and the urinary 
tract, whereas the remaining 30% is derived from plasma.19 
We hypothesized that the latter fraction may be informative 
on cardiac and cardiovascular disease. The multidimensional 
urinary classifier HF1 combines information on 85 urinary 
peptides,6 mainly upregulated and downregulated collagen 
fragments (Table S2). Patients with left ventricular dysfunc-
tion are characterized by a disturbed balance between colla-
gen synthesis and degradation in the extracellular matrix of 
the myocardium and an increased interstitial deposition and 
cross-linking of type I collagen.20 The cardiac extracellular 
matrix is predominantly composed of fibrillar collagen type I 
(85%) and type III (11%). Furthermore, small amounts of col-
lagen types IV and V codistribute with collagen I. The prime 
location of collagen V is at the fibril core and is important 
in nucleating collagen I–containing fibrils.21 The HF1 classi-
fier also includes a downregulated peptide derived from the 
WW domain-binding protein 11 (Table S2) that remained 
statistically significant after adjustment for multiple testing.6 
WBP11 is an inhibitor of protein phosphatase-1.22 In cardio-
myocytes, protein phosphatase-1 plays a key role in calcium 
handling and relaxation via dephosphorylation of phosphol-
amban.23 In patients with heart failure, the activity of protein 
phosphatase-1 is enhanced, thereby delaying left ventricular 
relaxation. In line with this pathophysiological pathway, inci-
dent heart failure represented 33.3% and 46.7% of the cardio-
vascular and cardiac events, respectively. We also considered 
whether reducing the multidimensionality of classifiers, 
such as HF1, might be possible without losing information. 
However, we previously demonstrated that a higher number of 
peptides resulted in higher accuracy by reducing variability in 
the assessment of single components.24 In an additional analy-
sis of the current data, we therefore tested a classifier based 
only on the 3 peptide biomarkers remaining significant after 
adjustment for multiple testing.6 As expected, this abridged 
classifier performed inferior to HF1 in diagnosing diastolic 
left ventricular dysfunction7 and in the prediction of cardio-
vascular and cardiac events (data not shown).
In population studies with long-term follow-up, blood pres-
sure is the main driver of cardiovascular risk.25,26 In our cur-
rent study, HF1 largely outperformed systolic blood pressure 
Figure 2. Cumulative incidence of cardiovascular (A) and cardiac end points (B) by thirds of the HF1 distribution. Estimates were 
standardized to the means of the distributions of sex and age in the whole study populations.
Table 2. Multivariable-Adjusted Hazard Ratios Associated With HF1 and Systolic Blood Pressure
End Points Events/At Risk
HF1 Systolic Blood Pressure
Hazard Ratio 
(95% CI) P Value R  2
Hazard Ratio 
(95% CI) P Value R 2
Cardiovascular events
  All participants 63/791 1.30 (1.03–1.65) 0.029 0.59 0.97 (0.74–1.28) 0.85 0.01
  Free of CVD 42/720 1.39 (1.03–1.87) 0.034 0.59 1.00 (0.72–1.39) 0.98 <0.0001
Cardiac events
  All participants 45/791 1.39 (1.06–1.84) 0.018 0.69 0.93 (0.67–1.29) 0.66 0.03
  Free of CVD 32/720 1.38 (0.98–1.95) 0.066 0.44 0.97 (0.66–1.40) 0.85 0.01
Hazard ratios express the risk per 1-SD increase in HF1 (0.92 U) and systolic blood pressure (17.7 mm Hg). Hazard ratios account for family 
clusters and were adjusted for baseline characteristics, including sex, age, fasting plasma glucose, smoking, and treatment with vasodilators 
(calcium-channel blockers [n=35] or α-blockers [n=4]). CVD indicates cardiovascular disease at entry. R ² is expressed in percent.
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in the prediction of cardiovascular and cardiac complications. 
These observations cannot be attributed to the quality of our 
blood pressure measurements, as exemplified by the absence 
of terminal digit and number preference. Several investiga-
tors have reported that single blood pressure measurements 
predicted the risk of cardiovascular disease over a follow-up 
Table 3. Optimized HF1 Thresholds in the Prediction of Cardiovascular and Cardiac Events
End Points
Optimal 
Discrimination Limit
Hazard Ratio  
(95% CI) Sensitivity, % Specificity, %
Positive Predictive 
Value, %
Negative Predictive 
Value, %
Misclassification 
Rate, %
Cardiovascular events
  All participants (n=791) –0.50 3.98 (2.41–6.57) 59 75 17 96 26
  Free of CVD (n=720) –1.22 4.84 (2.04–11.5) 86 46 9 98 52
Cardiac events
  All participants (n=791) –0.36 5.01 (2.77–9.05) 58 80 15 97 22
  Free of CVD (n=720) –0.36 4.58 (2.29–9.18) 53 81 12 97 20
The optimal discrimination limit was obtained by maximizing Younden’s index (the maximum of sensitivity plus specificity minus 1). Hazard ratios (95% 
confidence interval) present the risk associated with exceeding the biomarker threshold. The hazard ratios were significant (P≤0.0003).
Figure 3. Five-year absolute risk of cardiovascular and cardiac events in relation to systolic blood pressure (A, B) at different categories 
of HF1 and in relation to HF1 (C, D) at different levels of systolic blood pressure. The analyses were standardized to the average of the 
distributions in the whole study population (mean or ratio) of sex, age, fasting plasma glucose, smoking, treatment with vasodilators 
(calcium-channel blockers or α-blockers). In A and B, the risk functions span the 5th to 95th percentile interval of systolic blood pressure 
and correspond to the low, medium, and high categories of HF1. In C and D, the risk functions span the 5th to 95th percentile intervals 
of HF1 and correspond to the low (<33th percentile), medium (33–66th percentile), and high (>66th percentile) categories of systolic 
blood pressure. P values are for the independent effect of HF1 (PHF1) and systolic blood pressure (pSBP). nP and ne indicate the number of 
participants at risk and the number of events.
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period of 15 to 50 years, but also that the impact of blood pres-
sure diminished with increasing duration of follow-up.27–34 The 
strongest evidence in this regards comes from the Framingham 
Heart Study.34 Vasan and coworkers used sex- and age-specific 
multivariable Cox regression to evaluate the association of 
current blood pressure (at baseline), recent antecedent blood 
pressure (average of readings for all available examinations 
1–10 years before baseline), and remote antecedent blood 
pressure (average for all available examinations 11–20 years 
before baseline) with the 10-year risk of new-onset cardio-
vascular disease in 2313 Framingham Study participants. 
During follow-up, cardiovascular disease occurred in 899 par-
ticipants. In multivariable-adjusted models, recent and remote 
antecedent blood pressure predicted the risk of cardiovascular 
disease incrementally over current blood pressure. This obser-
vation was consistent in multiple subgroups: women (n=1403) 
and men (n=910) and 3 age strata (60–69, 70–79, and ≥80 
years).34 Explanations offered by the Framingham investiga-
tors were that antecedent blood pressure is a forerunner of car-
diovascular target organ damage, which is on the path to hard 
cardiovascular complications, and that the relation between 
cardiovascular risk and blood pressure might be weakened by 
the initiation of antihypertensive drug treatment.34 Our current 
findings remained consistent after exclusion of participants 
with a history of cardiovascular disease. Similarly, estimates 
of the hazard ratios remained confirmatory if we forced hyper-
tension as covariable in the Cox models or if we limited the 
analyses to participants untreated for hypertension at baseline 
(data not shown).
Use of vasodilators, calcium-channel blockers or 
α-blockers, at baseline was among the significant predictors 
of cardiovascular or cardiac events, for which our analyses 
were adjusted. Although resulting from an observational 
study, our findings are not surprising in view of the results 
of the Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT).35–37 In ALLHAT, use of 
doxazosin or amlodipine, compared with chlorthalidone was 
associated with an increased risk of combined cardiovascular 
disease. This secondary end point was driven by congestive 
heart failure35–37 and coronary revascularization,35–37 and for 
doxazosin also by hospitalized or treated angina pectoris.37 
Diuretics, β-blockers, angiotensin-converting enzyme inhibi-
tors, and angiotensin type-1 receptor blockers are drug classes 
used in the primary and secondary prevention of cardiovascu-
lar complications, in particular heart failure, but in our current 
study, use of these drug classes at baseline did not predict car-
diovascular or cardiac complications.
To our knowledge, there is no other population-based 
study that explored the value of the urinary proteome 
in predicting cardiovascular or cardiac complications. 
Nevertheless, our study must be interpreted within the 
context of its limitations. First, the sample size and num-
ber of events were substantially smaller than, for instance, 
in the Framingham Heart Study.34 This might explain why 
we could not show any significant prognostic value of HF1 
in relation to the incidence of mortality or coronary events. 
Second, our current study with a median follow-up of 6.1 
years does not allow to compare the prognostic value of HF1 
and blood pressure over a longer follow-up. Third, we did 
not assess the incremental predictive value of HF1 with other 
biomarkers of risk, such as high-sensitivity C-reactive pro-
tein38 or high-sensitivity troponin T.39
Perspectives
Our current study demonstrated that the urinary proteome, but 
not systolic pressure, predicts incident cardiovascular and car-
diac disease over a 5-year period and thereby confirmed the 
diagnostic utility of the urinary proteomic signature.6–8 Further 
prospective studies should underpin its use in clinical prac-
tice compared with other biomarkers over varying intervals of 
follow-up in relation to different end points. A previous publi-
cation in the same cohort demonstrated that the early diastolic 
peak velocity of the mitral annulus (e′) predicts the incidence 
of fatal combined with nonfatal cardiovascular events over 
a 5-year follow-up period.17 When we introduced both HF1 
and e′ in multivariable-adjusted models (62 cardiovascular 
and 44 cardiac events in 776 participants who underwent an 
assessment of their diastolic left ventricular function; data not 
shown), both were predictive, albeit with borderline P values 
(0.020≤P≤0.097), reflecting complementarity of information. 
Table 4. Integrated Discrimination Improvement and Net Reclassification 
Improvement by Adding HF1 to the Basic Model Including Covariables
End Points
Integrated Discrimination 
Improvement
Net Reclassification  
Improvement
IDI, % CI, % P Value NRI, % CI, % P Value
Cardiovascular events
  All participants (n=791) 1.89 0.54–3.24 0.006 49.9 24.6–75.2 0.0001
  Free of CVD (n=720) 2.13 1.33–2.93 <0.0001 63.8 41.3–86.2 <0.0001
Cardiac events
  All participants (n=791) 2.00 0.60–3.40 0.005 46.1 16.5–75.8 0.002
  Free of CVD (n=720) 1.34 0.61–2.73 0.061 31.0 −4.37 to 66.3 0.086
The basic reference models included as covariables sex, age, fasting plasma glucose, smoking, and treatment 
with vasodilators. The IDI is the difference between the discrimination slopes of basic models and basic models 
extended with HF1. The discrimination slope is the difference in predicted probabilities (%) between cases and 
controls. Controls are participants without incident cardiovascular or cardiac disease. The NRI is the sum of the 
net percentages of subjects reclassified correctly in cases and controls. CI indicates confidence interval; IDI, 
integrated discrimination improvement; and NRI, net reclassification improvement.
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However, for screening purposes, HF1 is less costly and 
labor-intensive than echocardiography and therefore prefer-
able. Having the urinary proteome confirmed as a short-term 
predictor of adverse outcomes might allow the timely initia-
tion of preventive or therapeutic measures. On the other hand, 
quality-of-life of patients confronted with a prognostically 
adverse urinary proteomic signature and cost-effectiveness 
remain issues of concern.
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What Is New?
•	 In a previous cross-sectional study, we identified a multidimensional 
urinary peptide-based classifier (HF1), which was associated with left 
ventricular dysfunction. In randomly recruited Flemish people, we inves-
tigated whether HF1 predicts cardiovascular end points over and beyond 
traditional risk factors.
What Is Relevant?
•	Over a 5 year follow-up period, the standardized and multivariable-ad-
justed hazard ratios relating cardiovascular (n=63) and cardiac (n=45) 
events with HF1 were 1.30 and 1.39 (P≤0.029), respectively, whereas 
those with systolic pressure were around unity (P≥0.66).
•	The diagnostic improvement obtained by adding optimized HF1 thresh-
olds to Cox models including classical cardiovascular risk factors, includ-
ing systolic blood pressure, was significant (P≤0.006).
Summary
Over ≈5 years of follow-up, the urinary proteome, but not systolic 
pressure, predicted incident cardiovascular disease. Further pro-
spective studies should confirm its diagnostic utility compared with 
other biomarkers over varying intervals of follow-up in relation to 
different end points. Having the urinary proteome confirmed as a 
short-term predictor of adverse outcomes might allow the timely 
initiation of preventive or therapeutic measures.
Novelty and Significance
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Expanded Methods  
Urinary Proteomics  
Aliquots of urine were stored at -80 °C.  Urine (0.7 mL) was thawed immediately before 
analysis and diluted with 0.7 mL of 2 M urea, 10 mM NH4OH containing 0.02% SDS.1  To 
remove higher molecular mass proteins, such as albumin and immunoglobulin G, the 
samples were ultrafiltered using Centrisart ultracentrifugation devices (20 kDa MWCO; 
Sartorius, Göttingen, Germany) at 2,000 g relative centrifugal force until 1.1 mL of filtrate was 
obtained.  This filtrate was then applied onto a PD-10 desalting column (GE Healthcare, 
Uppsala, Sweden) equilibrated in 0.01% NH4OH in HPLC-grade H2O (Roth, Germany) to 
decrease matrix effects by removing urea, electrolytes, and salts, and to enrich peptides.  
Finally, all samples were lyophilized, stored at 4 ºC, and suspended in HPLC-grade H2O 
shortly before capillary electrophoresis coupled with mass spectrometry (CE-MS).   
As described in detail elsewhere,2 CE-MS analyses were performed using a P/ACE MDQ 
capillary electrophoresis system (Beckman Coulter, Brea, CA) on-line coupled to a 
micrOTOF MS (Bruker Daltonic, Bremen, Germany).  The ESI sprayer (Agilent Technologies, 
Palo Alto, CA) was grounded, and the ion spray interface potential was set between -4 
and -4.5 kV.  Data acquisition and mass spectrometry acquisition methods were 
automatically controlled by the capillary electrophoresis via contact-close-relays.  Spectra 
were accumulated every 3 seconds, over a range of charge states (m/z) 350 to 3000.  
Previous publications described the accuracy, precision, selectivity, sensitivity, reproducibility, 
and stability of the CE-MS measurements in detail. 2,3   
Mass spectra were processed using MosaiquesVisu software, including peak picking, 
deconvolution and deisotoping.4  Migration time and peak intensity were normalized using 
internal peptide standards.5  These fragments result from normal biological processes and 
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appear to be unaffected by any disease state studied to date based on over 20,000 samples 
in the Mosaiques database.6  The resulting list of peaks characterizes each peptide by its 
molecular mass, normalized capillary electrophoresis migration time, and normalized signal 
intensity.  All detected peptides were deposited, matched, and annotated in a Microsoft SQL 
database, allowing further analysis and comparison of multiple patient groups.  Peptide 
fragments were combined into a single summary variable, using the support-vector machine 
based MosaCluster software, version 1.6.5.   
In the present study, we used the previously published multidimensional classifier, which 
is associated with decreased left ventricular function and which combines information from 
85 peptide fragments identified in 19 patients with diastolic LV dysfunction and 19 controls.7  
The classifier established by SVM modelling allows the classification of samples in the high 
dimensional data space.  MosaCluster calculates classification scores based on the 
amplitudes of all HF1 biomarkers in the different samples.  Classification is performed by 
determining the Euclidian distance (defined as the SVM classification score) of the vector to 
a maximal margin separating hyperplane.  The SVM classifier uses the log transformed 
intensities of the urinary peptides as coordinates in an N-dimensional space.  For HF1, N 
equals to 85.  The SVM classifier then builds an N – 1 dimensional hyperplane that spans 
this space by performing a quadratic programming optimization of a Lagrangian, using the 
training labels only while allowing for samples to lie at the wrong side of the plane.  For such 
mistakes in classification the SVM introduces a cost parameter C.  Because non-separable 
problems in low dimensions may be separable in higher dimensions, the SVM uses the 
Kernel-trick to transform the data to a higher dimensional space.  MosaCluster uses the 
standard radial basis functions as kernel.  These functions are just Gaussians with the 
parameter gamma controlling their width.  The optimal parameters C and gamma are found 
via cross validation error estimation, using a lattice build by different values of these two 
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parameters. SVMs are frequently implemented in data mining software.  In particular, the 
kernlab cran R package is a versatile tool for building SVM based-classifiers.   
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Table S1.   List of 85 Peptides Included in the HF1 Biomarker   
Peptide  Cases  Controls  
ID Mass (Da) 
CE Time 
(min) % MA % MA R 
P-value 
(Unadjusted)
81272 2211.98 33.23 0 0 0.42 2.67 0 1.99E-03 
129821 3333.36 19.42 0 0 0.47 2.39 0 8.72E-04 
8725 949.4 25.79 0.05 1.94 0.63 2.28 0.067 2.22E-04 
123106 3130.43 30.82 0.05 1.98 0.47 2.63 0.080 2.57E-03 
1577 840.41 23.17 0.05 1.65 0.47 1.85 0.095 3.29E-03 
103493 2658.22 19.5 0.05 3.36 0.47 3.29 0.109 4.71E-03 
44146 1518.6 19.37 0.11 1.91 0.58 2.49 0.145 1.33E-03 
4845 900.27 43.66 0.16 1.55 0.63 2.44 0.161 1.33E-03 
37610 1421.59 38.71 0.11 1.73 0.53 1.87 0.192 6.07E-03 
83441 2248.97 33.69 0.11 3.45 0.53 3.56 0.201 4.88E-03 
74703 2087.84 19.42 0.11 2.64 0.53 2.7 0.203 6.76E-03 
101157 2616.16 28.39 0.11 1.97 0.53 1.98 0.206 6.76E-03 
103022 2649.2 34.85 0.16 2.52 0.68 2.56 0.232 2.50E-03 
57360 1734.66 19.9 0.16 2.2 0.58 2.24 0.271 1.03E-02 
46091 1554.66 28.59 0.16 2.08 0.53 2.24 0.280 1.18E-02 
32022 1319.58 20.89 0.21 1.99 0.58 2.21 0.326 1.57E-02 
102269 2638.18 28.42 0.26 2.3 0.68 2.49 0.353 1.26E-02 
82708 2235.04 34.17 0.32 2.57 0.84 2.68 0.365 2.53E-03 
188895 11967.55 20.47 0.26 2.68 0.63 2.94 0.376 9.50E-03 
98089 2559.18 19.41 0.32 2.97 0.84 3 0.377 3.76E-03 
138143 3593.47 20.2 0.26 2.67 0.68 2.68 0.381 1.50E-02 
167786 4771.07 20.2 0.37 2.74 0.79 3.13 0.410 4.34E-03 
61984 1835.71 19.91 0.53 2.64 1 3.12 0.448 1.33E-04 
46369 1560.7 29.79 0.32 2.78 0.68 2.84 0.461 2.27E-02 
143947 3801.77 33.46 0.37 2.26 0.79 2.24 0.473 2.67E-02 
39275 1445.62 37.36 0.47 2.59 0.79 2.96 0.521 4.87E-03 
56493 1716.66 20.18 0.47 2.56 0.79 2.74 0.556 2.11E-02 
41972 1478.61 39.3 0.53 2.75 0.84 2.95 0.588 3.16E-03 
24168 1195.48 37.51 0.58 2.8 0.84 3.26 0.593 3.12E-03 
107858 2751.34 29.23 0.63 2.36 0.89 2.69 0.621 3.00E-03 
23356 1179.52 37.49 0.58 2.63 0.84 2.9 0.626 2.67E-02 
97599 2547.99 21.44 0.58 2.59 0.89 2.66 0.635 3.15E-02 
8695 949.22 34.33 0.53 2.46 0.68 3.01 0.637 2.78E-02 
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Peptide  Cases  Controls  
ID Mass (Da) 
CE Time 
(min) % MA % MA R 
P-value 
(Unadjusted)
23697 1186.53 22.39 0.68 2.8 1 2.88 0.661 2.08E-02 
36566 1401.38 36.56 0.58 2.77 0.74 3.27 0.664 8.74E-03 
153832 4196.75 20.84 0.68 2.41 0.95 2.59 0.666 4.93E-03 
26670 1235.56 26.65 0.63 3.02 0.84 3.3 0.686 1.08E-02 
58050 1749.81 30.61 0.63 2.57 0.84 2.79 0.691 3.04E-02 
28005 1255.48 35.77 0.68 3.08 0.84 3.4 0.733 3.19E-02 
159396 4409.89 20 0.74 2.72 0.84 3.23 0.742 2.68E-02 
69979 1996.79 20.98 0.79 2.86 0.95 3.17 0.750 8.53E-03 
40737 1462.62 39.42 0.84 3.33 1 3.68 0.760 2.62E-04 
65368 1901.82 43.83 0.79 3.17 0.89 3.61 0.779 1.52E-02 
128086 3286.55 30.92 0.79 3.13 0.89 3.51 0.792 6.91E-04 
73434 2067.82 20.62 0.84 3.1 1 3.28 0.794 1.42E-02 
148086 3986.65 20.6 0.84 3.53 0.95 3.82 0.817 2.75E-03 
108574 2764.21 42.63 0.79 3.56 0.89 3.85 0.821 2.43E-02 
90344 2377.1 20.8 0.89 3.12 0.95 3.46 0.845 1.95E-02 
36759 1405.61 39.04 0.89 2.94 0.95 3.18 0.866 1.02E-02 
147541 3968.6 21.09 0.89 3.14 0.89 3.57 0.880 1.77E-03 
28561 1265.59 27.09 0.89 3.36 0.89 3.79 0.887 1.10E-02 
107460 2742.25 28.98 0.95 2.91 1 3.11 0.889 1.19E-02 
32171 1321.59 28.37 0.95 4.07 1 4.27 0.906 1.82E-02 
39322 1446.64 39.43 1 3.2 1 3.49 0.917 3.19E-02 
35339 1378.61 28.82 1 3.36 1 3.53 0.952 1.54E-02 
81196 2210.95 33.61 1 3.72 1 3.59 1.036 2.15E-02 
41601 1469.67 23.69 1 3.72 1 3.56 1.045 2.33E-02 
62866 1854.81 40.92 1 3.89 1 3.71 1.048 1.98E-02 
99021 2570.19 42.56 1 3.88 1 3.7 1.049 1.19E-02 
79136 2175 33.28 1 3.74 1 3.49 1.072 1.09E-02 
50840 1623.73 24.12 0.95 4.17 0.95 3.86 1.080 9.77E-03 
72533 2046.92 32.58 0.95 3.49 0.95 3.21 1.087 1.06E-02 
57537 1737.78 23.73 1 4.02 0.95 3.82 1.108 2.15E-02 
50212 1613.82 23.99 0.89 2.7 0.89 2.43 1.111 3.30E-02 
60149 1794.8 23.92 1 3.72 0.95 3.47 1.128 6.20E-03 
103198 2654.19 23.92 0.89 2.94 0.89 2.47 1.190 5.52E-03 
104786 2679.2 23.53 1 3.58 0.89 3.34 1.204 7.89E-03 
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Peptide  Cases  Controls  
ID Mass (Da) 
CE Time 
(min) % MA % MA R 
P-value 
(Unadjusted)
33135 1338.6 23.99 1 2.86 0.89 2.65 1.213 1.20E-02 
73291 2064.92 24.46 0.84 2.75 0.79 2.37 1.234 3.25E-02 
45021 1532.62 26.35 1 2.82 0.89 2.55 1.243 1.67E-02 
99475 2577.25 24.67 0.95 2.78 0.89 2.38 1.247 6.05E-03 
40294 1452.66 23.61 1 2.85 0.84 2.62 1.295 2.17E-03 
35424 1380.64 23.83 0.95 2.79 0.79 2.56 1.311 7.17E-03 
131294 3375.57 31.92 1 2.87 0.79 2.71 1.341 1.80E-02 
111564 2841.26 24.54 0.89 3.21 0.79 2.67 1.354 4.98E-03 
104195 2663.2 23.51 0.89 2.61 0.74 2.29 1.371 2.07E-02 
28747 1268.57 27.25 1 3.44 0.74 3.32 1.400 1.01E-02 
44802 1526.69 23.92 0.79 2.51 0.63 2.1 1.499 1.10E-02 
113452 2889.35 24.08 0.89 2.47 0.58 2.29 1.655 7.34E-03 
69681 1989.88 32.44 0.84 2.43 0.42 2.51 1.936 2.03E-02 
55516 1696.72 23.95 0.79 2.54 0.42 2.39 1.999 1.59E-02 
80360 2196.02 33.16 0.68 2.74 0.26 2.73 2.625 1.15E-02 
82784 2236.98 27.14 0.63 2.28 0.21 2.31 2.961 1.29E-02 
56806 1723.52 37.74 0.53 2.31 0.11 2.52 4.417 1.03E-02 
129182 3320.51 24.25 0.47 2.07 0.05 2.1 9.266 4.71E-03 
ID, peptide identifier (SQL number); %, percentage of samples, in which the peptide could be detected; MA, mean signal 
amplitude of the peptides. R was calculated as ∑ (ln signal amplitude x frequency/number of participants) in cases divided 
by ∑ (ln signal amplitude x frequency/number of participants) in controls.  The peptides were ordered by ascending R.  
Reproduced from reference 7.   
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Table S2.   List of Peptides Included in HF1 with Available Information on Amino-Acid Sequence   
ID  Sequence of Peptide  Protein Name  
Cases   Controls 
% MA  % MA R 
8725 GDAGSKGpmV Collagen alpha-1(V) 0.05 1.94  0.63 2.28 0.067 
123106 RDVEEEEEEEGLEEDAELLTELQEVLG Coiled-coil and C2 domain-containing protein 1B 0.05 1.98  0.47 2.63 0.080 
1577 KGDTGPpGP Collagen alpha-1(III) 0.05 1.65  0.47 1.85 0.095 
103493 DEAGSEADHEGTHSTKRGHAKSRPV Fibrinogen alpha 0.05 3.36  0.47 3.29 0.109 
44146 DDFDAHKALEDDE Isoform 1 of Histone-lysine N-methyltransferase MLL2 0.11 1.91  0.58 2.49 0.146 
4845 GGSGAmGSmD 
Immunoglobulin-like and fibronectin type III domain-
containing protein 1 
0.16 1.55 
 
0.63 2.44 0.161 
37610 GPpGpPGSpGEQGPSG Collagen alpha-1(I) 0.11 1.73  0.53 1.87 0.192 
83441 GAVGEKGEPGEAGEpGLpGEGGPpG Collagen alpha-1(V) 0.11 3.45  0.53 3.56 0.201 
74703 KSSSHQDSSRmSSVGDYNT Bone morphogenetic protein 5 0.11 2.64  0.53 2.7 0.203 
101157 GPpGADGQpGAKGEpGDAGAKGDAGpPGPA Collagen alpha-1(I) 0.11 1.97  0.53 1.98 0.207 
103022 FNINNLDNNWLKMHFWFYYA Dermatan-sulfate epimerase-like protein 0.16 2.52  0.68 2.56 0.232 
46091 KGETGDVGQMGppGPP Collagen alpha-1(V) 0.16 2.08  0.53 2.24 0.280 
32022 TYFPHFDLSHG Hemoglobin subunit alpha 0.21 1.99  0.58 2.21 0.326 
82708 GRTGDAGPVGPPGPpGppGpPGPPS Collagen alpha-1(I) 0.32 2.57  0.84 2.68 0.365 
98089 DEAGSEADHEGTHSTKRGHAKSRP Fibrinogen alpha  0.32 2.97  0.84 3 0.377 
61984 DQDKHDDSTDDSDTDK WW domain-binding protein 11 0.53 2.64  1 3.12 0.448 
46369 GPpGEKGGQGPPGpQGp Collagen alpha-1(V) 0.32 2.78  0.68 2.84 0.461 
143947 
DQGPVGRTGEVGAVGPpGFAGEKGPSGEA 
GTAGPpGTpGPQG 
Collagen alpha-2(I) 0.37 2.26 
 
0.79 2.24 0.472 
39275 DGVGQpGLPGpPGPpG Collagen alpha-1(XVIII) 0.47 2.59  0.79 2.96 0.520 
56493 KGDEGEAGDPGDDNNDI Collagen alpha-1(VI) 0.47 2.56  0.79 2.74 0.556 
41972 EQGLpGAAGQDGPpGP Isoform D preproprotein of collagen alpha-1 (XI) 0.53 2.75  0.84 2.95 0.588 
24168 GPpGPPGPSSNQG Collagen alpha-6(IV) 0.58 2.8  0.84 3.26 0.593 
107858 VSESSIHIIGVSLGAHVGGmVGQLFGGQ Isoform 2 of phospholipase A1 member A 0.63 2.36  0.89 2.69 0.621 
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ID  Sequence of Peptide  Protein Name  
Cases   Controls 
% MA  % MA R 
23356 GPpGPpGPSSNQG Collagen alpha-6(IV) 0.58 2.63  0.84 2.9 0.626 
97599 LGSHSQDEEDEDTEYFDAMEDS 101 kDa protein 0.58 2.59  0.89 2.66 0.634 
23697 DDGEAGKpGRpG Collagen alpha-1(I) 0.68 2.8  1 2.88 0.661 
36566 EEEDSSDSSSDSE Isoform 1 of AP-3 complex subunit beta-1 0.58 2.77  0.74 3.27 0.664 
26670 GQDGRpGPpGPpG Collagen alpha-1(I) 0.63 3.02  0.84 3.3 0.686 
58050 GPpGEAGKpGEQGVPGDLG Collagen alpha-1(I) 0.63 2.57  0.84 2.79 0.691 
28005 TYFPHFDLSHG Hemoglobin subunit alpha 0.68 3.08  0.84 3.4 0.733 
69979 KGSpGSDGpKGEKGDPGpEGP Isoform 2C2A' of collagen alpha-2(VI) chain 0.79 2.86  0.95 3.17 0.750 
40737 GPpGPAGNpGpSpNSP Isoform 1 of collagen alpha-1(XXVI) 0.84 3.33  1 3.68 0.760 
65368 WIDAPDDVFYMATEET Metastasis-associated protein MTA1  79 kDa protein 0.79 3.17  0.89 3.61 0.779 
73434 ADGSDLDAVSHGSmDSGHGTH C-myc promoter-binding protein isoform 1 0.84 3.1  1 3.28 0.794 
108574 DmGPpGPQGPpGKDGPPGVKGENGHPGSP Isoform 2 of collagen alpha-1 (XIII)  0.79 3.56  0.89 3.85 0.821 
90344 GKNGDDGEAGKpGRpGERGPpGPQ Collagen alpha-1(I) 0.89 3.12  0.95 3.46 0.845 
36759 PpGPpGFPGDpGPpG Collagen alpha-3(V) 0.89 2.94  0.95 3.18 0.866 
28561 SpGPDGKTGPpGPA Collagen alpha-1(I) 0.89 3.36  0.89 3.79 0.886 
107460 KNGETGPQGPPGPTGPGGDKGDTGPpGpQG Collagen alpha-1(III) 0.95 2.91  1 3.11 0.889 
32171 ApGDRGEpGPpGPA Collagen alpha-1(I) 0.95 4.07  1 4.27 0.905 
39322 GPpGPpGFPGDPGPpG Collagen alpha-3(V) 1 3.2  1 3.49 0.917 
35339 ApGEDGRpGPpGPQ Collagen alpha-1(II) 1 3.36  1 3.53 0.952 
81196 NGApGNDGAKGDAGApGApGSQGApG Collagen alpha-1(I) 1 3.72  1 3.59 1.036 
41601 DGQPGAKGEpGDAGAK Collagen alpha-1(I) 1 3.72  1 3.56 1.045 
62866 SGpQGppGSEGFTGPPGPQG Collagen alpha-2(IV) 1 3.89  1 3.71 1.048 
99021 QQEQLQQQQFQQQQEQLQQQ Zinc finger protein 853 1 3.88  1 3.7 1.049 
79136 AGPpGEAGKpGEQGVpGDLGApGP Collagen alpha-1(I) 1 3.74  1 3.49 1.072 
50840 DGApGKNGERGGpGGpGP Collagen alpha-1(III) 0.95 4.17  0.95 3.86 1.080 
72533 PpGEAGKpGEQGVpGDLGApGP Collagen alpha-1(I) 0.95 3.49  0.95 3.21 1.087 
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ID  Sequence of Peptide  Protein Name  
Cases   Controls 
% MA  % MA R 
57537 NDGApGKNGERGGpGGpGP Collagen alpha-1(III) 1 4.02  0.95 3.82 1.108 
50212 VGGGEQPPPAPAPRRE Xylosyltransferase 1 0.89 2.7  0.89 2.43 1.111 
60149 GNDGApGKNGERGGpGGpGP Collagen alpha-1(III) 1 3.72  0.95 3.47 1.128 
103198 ERGEAGIpGVpGAKGEDGKDGSpGEpGA Collagen alpha-1(III) 0.89 2.94  0.89 2.47 1.190 
104786 NRGERGSEGSPGHpGQpGppGpPGAPGP Collagen alpha-1(III) 1 3.58  0.89 3.34 1.204 
33135 GAPGPRGRDGEpGT Isoform 1 of collagen alpha-1(II) 1 2.86  0.89 2.65 1.213 
73291 DDKDEEDSPRPRSPPGGPD Zinc finger and BTB domain-containing protein 46 0.84 2.75  0.79 2.37 1.234 
45021 RDGEPGTPGNpGPpGP Isoform 1 of collagen alpha-1(II) 1 2.82  0.89 2.55 1.243 
99475 DDILASPPRLPEPQPYPGAPHHSS Collagen alpha-1(XVIII) 0.95 2.78  0.89 2.38 1.246 
40294 DEPPQSPWDRVK Apolipoprotein A-I 1 2.85  0.84 2.62 1.295 
35424 AMFGPKGFGRGGAE Cysteine-rich protein 1 0.95 2.79  0.79 2.56 1.311 
131294 PGEDGEpGRNGNPGEVGFAGSpGARGFPGAPGLPGL Collagen alpha-2(V) 1 2.87  0.79 2.71 1.341 
111564 ERGEAGIpGVpGAkGEDGKDGSpGEpGANG Collagen alpha-1(III) 0.89 3.21  0.79 2.67 1.354 
104195 NRGERGSEGSPGHPGQPGPpGppGApGP Collagen alpha-1(III) 0.89 2.61  0.74 2.29 1.371 
28747 SpGERGETGPpGP Collagen alpha-1(III) 1 3.44  0.74 3.32 1.400 
44802 GGAGEpGKNGAKGEpGp Isoform 1 of collagen alpha-1(III) 0.79 2.51  0.63 2.1 1.499 
113452 NGEAGSAGPpGppGLRGSpGSRGLPGADGRAG Collagen alpha-2(I) 0.89 2.47  0.58 2.29 1.655 
69681 SNGNpGPpGPSGSpGKDGPpGP Collagen alpha-1(III) 0.84 2.43  0.42 2.51 1.936 
55516 RGSGGGGGGGGQGSTNYGKS Isoform 3 of heterogeneous nuclear ribonucleoprotein A/B 0.79 2.54  0.42 2.39 1.999 
80360 ISVPGPMGPSGPRGLpGPpGApGP Collagen alpha-1(I) 0.68 2.74  0.26 2.73 2.625 
82784 ADGQpGAkGEpGDAGAKGDAGPpGP Collagen alpha-1(III) 0.63 2.28  0.21 2.31 2.961 
ID, peptide identifier (SQL number); %, percentage of samples, in which the peptide could be detected; MA, mean signal amplitude of the peptides. R was calculated as ∑ (ln signal amplitude x 
frequency/number of participants) in controls divided by ∑ (ln signal amplitude x frequency/number of participants) in cases. The peptides were ordered by ascending R.   
Reproduced from reference 7.   
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Table S3.   Fatal and Nonfatal Cardiovascular Events  
Endpoint  Type  Number of events  
Stroke  Fatal  3  
 Nonfatal  3  
Transient ischaemic attack  Nonfatal  5  
Myocardial infarction  Fatal  2  
 Nonfatal  3  
Acute coronary syndrome  Nonfatal  1 
Angina pectoris Nonfatal 1 
Ischaemic cardiomyopathy  Nonfatal  17  
Coronary revascularisation  Nonfatal  16  
Congestive heart failure  Fatal  5  
 Nonfatal  16  
Atrial fibrillation/arrhythmia  Nonfatal  6  
Atrioventricular block  Nonfatal  3  
Aortic aneurysm  Fatal  1  
 Nonfatal  2  
Pulmonary heart disease  Nonfatal  1  
Arterial embolism  Nonfatal  1  
Peripheral arterial diseases   Nonfatal  9  
Total number   95  
Follow-up of the 791 participants spanned a median of 6.1 years (5th to 95th percentile interval, 
3.7–7.4).  A participant can experience multiple nonfatal events, so that nonfatal events do not 
add up.  In the outcome analyses, only the first event within each category was considered.   
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Table S4.   Crude Event Rates by Thirds of the HF1 Distribution   
Endpoint  
(number of events)  
<–1.42 (n=264)   –1.42 to –0.68 (n=263)   ≥ –0.68 (n=264)  
n  Rate (95% CI)   n  Rate (95% CI )  n  Rate (95% CI) 
Total mortality (n=35)  7  4.7 (4.6, 4.8)   9  5.9 (5.7, 6.0)   19  12.5 (12.4, 12.7)  
Cardiovascular events (n=63)  8  5.4 (5.3, 5.5)   17  11.4 (11.2, 11.6)   38  26.9 (26.6, 27.2)  
Cardiac events (n=45)  4  2.7 (2.6, 2.8)   13  8.7 (8.5, 8.8)   28  19.4 (19.1, 19.6)  
Coronary events (n=22)  3  2.0 (1.9, 2.1)   4  2.6 (2.5, 2.7)   15  10.2 (10.0, 10.4)  
Rates (95% confidence interval) are expressed as number of events per 1000 person-years.  
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Table S5.   Covariables Associated with Cardiovascular and Cardiac Risk Selected by a Step-Down Procedure  
Selected  
covariables  
 Cardiovascular events   Cardiac events  
 Hazard ratio (95% CI)  P   Hazard ratio (95% CI)  P  
Being female (0,1)   0.57 (0.34–0.95)  0.031   0.56 (0.31–1.03)  0.063  
Age (+15.7 years)   3.63 (2.55–5.17)  <0.0001   3.21 (2.04–5.07)  <0.0001  
Fasting plasma sugar (+0.78 mmol/L)   1.17 (0.99–1.39)  0.063   1.30 (1.10–1.52)  0.002  
Smoking (0, 1)   2.57 (1.43–4.60)  0.002   1.83 (0.89–3.78)  0.10  
On treatment with vasodilators (0, 1)   2.04 (1.03–4.02)  0.040   2.86 (1.39–5.91)  0.005  
For age and fasting plasma glucose, hazard ratios express the risk per 1-SD increase in the explanatory variable.  Models accounted for clustering of 
failure times within pedigrees.  The baseline characteristics considered as potential covariables were sex, age, body mass index, systolic blood pressure, 
fasting plasma glucose, the total-to-HDL cholesterol ratio, -glutamyltransferase (as index of alcohol intake), smoking, history of cardiovascular disease, 
and treatment with diuretics (thiazides, loop diuretics and aldosterone antagonists), -blockers, inhibitors of the renin-angiotensin system (angiotensin-
converting-enzyme inhibitors or angiotensin type-1 receptor blockers), vasodilators (calcium-channel blockers or -blockers), or other antihypertensive 
drugs.  Covariables to be retained in the analysis were identified by a step-down procedure, removing the least significant covariable at each step until all 
P-values of covariables were less than 0.15.   
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Figure S1.   Flow chart.   
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Figure S2.   Distribution of the urinary multi-dimensional biomarker HF1 in 791 participants.  The 
curves represent the fitted normal (full line) and kernel (dashed line) density plots.  S and K are the 
coefficients of skewness and kurtosis, respectively.  The P-value is for the Kolmogorov–Smirnov test 
and indicates departure from normality.   
